Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Certified trichologist Bridgette Hill agrees and adds that exfoliating the scalp can help improve circulation and decongest ...

Psoriatic arthritis is a combination of psoriasis and arthritis symptoms. You may have skin and nail changes, joint pain and ...

Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Marisa Garshick, MD, a board-certified dermatologist and clinical assistant professor, discusses resources and tools that can ...

Patent protection for ZORYVE cream 0.3% extends until at least 2037. ZORYVE cream 0.3% is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

My first experience with the condition was in my third year in high school. It started as subtle red bumps along my hairline, which gradually turned scaly. Soon after, I was experiencing dandruff, and ...

Spots can also look very different depending on your skin tone. Some pink, red, or brown spots are more obvious on fair to ...